NEW YORK, Oct. 15 -- Samuel Waksal, co-founder and former chief executive of ImClone Systems Inc., pleaded guilty to criminal securities fraud, obstruction of justice, perjury and bank fraud today ...

ImClone Systems, a biotechnology company focused on developing cancer medicines, said yesterday it was considering a buyout offer from a "large pharmaceutical company" that easily tops an earlier ...

ImClone Systems Inc.'s high-water mark was a sweet deal last fall in which its shareholders were allowed to sell a portion of their holdings to drug giant Bristol-Myers Squibb Co. for $70 a share.

Biotech company ImClone System Inc. faces questions over the failure to get cancer drug Erbitux to market, both at its annual meeting on Tuesday and at a congressional hearing later in the week.

Most biotech companies would kill for a little exposure. ImClone Systems almost died from it four years ago, and it's in for another gloppy ladling of buzz - welcome or not - now that legendary ...

Former ImClone Systems CEO Sam Waksal, whose insider trading scandal landed him and close friend Martha Stewart behind bars, is getting back into the biotech game.

ImClone Systems Inc. said it agreed in principle to settle two lawsuits related to the failed regulatory application for its cancer drug Erbitux.

PHARMACEUTICALS * ImClone Systems Inc. may be the subject of additional hearings by the House Energy and Commerce Committee, Chairman W.

Carl Icahn may have failed to secure a deal for Internet icon Yahoo! but he’s well on his way to ginning up a bidding war for drug company ImClone Systems. Icahn, who is chairman of the cancer ...

LONDON (MarketWatch) -- ImClone SystemsLONDON (MarketWatch) -- ImClone Systems said in a filing to the Securities and Exchange Commission that Carl Icahn is against a $36 a share takeover offer ...